Literature DB >> 30789396

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Erin Gomez1, Phuoc T Tran2, Kenneth J Pienta3, Martin G Pomper, Michael A Gorin, Steven P Rowe.   

Abstract

We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30789396      PMCID: PMC6399051          DOI: 10.1097/RLU.0000000000002489

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  10 in total

1.  Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Jeffrey P Leal; Takahiro Higuchi; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

2.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

4.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

Review 5.  PET in Benign Bone Marrow Disorders.

Authors:  Wouter van der Bruggen; Andor W J M Glaudemans; Edo Vellenga; Riemer H J A Slart
Journal:  Semin Nucl Med       Date:  2017-03-17       Impact factor: 4.446

Review 6.  Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL.

Authors:  Steven P Rowe; Michael A Gorin; Martin G Pomper
Journal:  PET Clin       Date:  2017-04-01

Review 7.  Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders.

Authors:  Lydie Da Costa; Julie Galimand; Odile Fenneteau; Narla Mohandas
Journal:  Blood Rev       Date:  2013-05-09       Impact factor: 8.250

Review 8.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 9.  Old and new insights into the diagnosis of hereditary spherocytosis.

Authors:  Olga Ciepiela
Journal:  Ann Transl Med       Date:  2018-09

Review 10.  Radionuclide imaging of bone marrow disorders.

Authors:  Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-13       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.